Corvus Pharmaceuticals Inc
CRVS4.255USD
+0.155+3.78%
Market hours （ET）Quotes delayed by 15 min
290.06MMarket Cap
LossP/E TTM
More Details of Corvus Pharmaceuticals Inc Company
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in patients with various recurrent, malignant T cell lymphomas. Soquelitinib is designed to inhibit the proliferation of certain malignant T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.
Company Info
Ticker SymbolCRVS
Company nameCorvus Pharmaceuticals Inc
IPO dateMar 23, 2016
CEODr. Richard A. Miller, M.D.
Number of employees31
Security typeOrdinary Share
Fiscal year-endMar 23
Address863 Mitten Rd Ste 102
CityBURLINGAME
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94010-1311
Phone16509004520
Websitehttps://www.corvuspharma.com/
Ticker SymbolCRVS
IPO dateMar 23, 2016
CEODr. Richard A. Miller, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Richard A. Miller, M.D.
Dr. Richard A. Miller, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.32M
+31.66%
Mr. Leiv Lea
Mr. Leiv Lea
Chief Financial Officer
Chief Financial Officer
282.44K
--
Dr. Linda S. Grais, M.D., J.D.
Dr. Linda S. Grais, M.D., J.D.
Independent Director
Independent Director
10.00K
--
Mr. Richard Van Den Broek
Mr. Richard Van Den Broek
Independent Director
Independent Director
--
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Mr. Jeffrey S. Arcara
Mr. Jeffrey S. Arcara
Senior Vice President, Chief Business Officer
Senior Vice President, Chief Business Officer
--
--
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Director
Independent Director
--
--
Mr. Ian T. Clark
Mr. Ian T. Clark
Independent Director
Independent Director
--
--
Dr. William B. Jones, Ph.D.
Dr. William B. Jones, Ph.D.
Senior Vice President - Pharmaceutical Development
Senior Vice President - Pharmaceutical Development
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Richard A. Miller, M.D.
Dr. Richard A. Miller, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
2.32M
+31.66%
Mr. Leiv Lea
Mr. Leiv Lea
Chief Financial Officer
Chief Financial Officer
282.44K
--
Dr. Linda S. Grais, M.D., J.D.
Dr. Linda S. Grais, M.D., J.D.
Independent Director
Independent Director
10.00K
--
Mr. Richard Van Den Broek
Mr. Richard Van Den Broek
Independent Director
Independent Director
--
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
Mr. Jeffrey S. Arcara
Mr. Jeffrey S. Arcara
Senior Vice President, Chief Business Officer
Senior Vice President, Chief Business Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 23
Updated: Wed, Jul 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
9.29%
Samlyn Capital, LLC
5.27%
Adams Street Partners, LLC
4.25%
Point72 Asset Management, L.P.
3.61%
RTW Investments L.P.
3.47%
Other
74.10%
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
9.29%
Samlyn Capital, LLC
5.27%
Adams Street Partners, LLC
4.25%
Point72 Asset Management, L.P.
3.61%
RTW Investments L.P.
3.47%
Other
74.10%
Shareholder Types
Shareholders
Proportion
Private Equity
15.59%
Hedge Fund
14.18%
Investment Advisor
8.52%
Investment Advisor/Hedge Fund
5.44%
Individual Investor
3.83%
Venture Capital
2.92%
Research Firm
1.31%
Pension Fund
0.24%
Bank and Trust
0.01%
Other
47.95%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
151
40.14M
52.05%
-1.55M
2025Q1
158
41.01M
55.15%
-1.27M
2024Q4
137
42.04M
65.42%
+8.08M
2024Q3
112
32.95M
52.86%
+765.53K
2024Q2
108
30.52M
48.98%
-5.02M
2024Q1
116
20.23M
41.14%
-8.66M
2023Q4
119
21.51M
43.96%
-7.95M
2023Q3
129
21.52M
44.20%
-7.79M
2023Q2
132
21.81M
46.84%
-8.41M
2023Q1
121
23.10M
49.61%
-7.89M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
OrbiMed Advisors, LLC
7.17M
9.29%
+221.35K
+3.19%
Jun 27, 2025
Samlyn Capital, LLC
4.07M
5.27%
-2.60M
-39.01%
Mar 31, 2025
Adams Street Partners, LLC
3.28M
4.25%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
2.79M
3.61%
-242.38K
-8.00%
Mar 31, 2025
RTW Investments L.P.
2.68M
3.47%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.49M
3.23%
+39.55K
+1.61%
Mar 31, 2025
Miller (Richard A)
2.32M
3.01%
+559.07K
+31.66%
May 07, 2025
Vivo Capital, LLC
2.23M
2.9%
--
--
Mar 31, 2025
Millennium Management LLC
1.64M
2.12%
+1.48M
+956.89%
Mar 31, 2025
Foresite Capital Management, LLC
1.58M
2.05%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
Invesco NASDAQ Future Gen 200 ETF
0.48%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
iShares Biotechnology ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
Global X Russell 2000 ETF
0.01%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.85%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.48%
iShares Micro-Cap ETF
Proportion0.05%
ProShares Ultra Nasdaq Biotechnology
Proportion0.03%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.03%
iShares Biotechnology ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
